ArticleNPJ precision oncology2026
Minigene-based characterization and classification of splice-associated variants in succinate dehydrogenase B.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathogenic germline variants in SDHB predispose to pheochromocytoma and paraganglioma, but limited functional evidence challenges clinical interpretation. To investigate splice-associated SDHB variants, we developed a minigene spanning exons 2-5 and assessed derived SDHB transcripts in HEK293T cells using targeted RNA sequencing. We evaluated 48 variants prioritized by SpliceAI (Δ≥0.42), two negative controls and endogenous SDHB, and compared findings with tumor data (n = 2). Nineteen variants (38%) showed ≥90% wildtype splicing, whereas 17 (34%) exhibited ≥90% aberrant splicing. Across all variants, 73 aberrant transcripts were observed (average of 2.3 per variant, 22 unique transcripts). Using a customized decision framework, RNA-based evidence strengths were assigned to 64 aberrant transcripts (88%). Among 26 classified variants, 10 received PVS1_Strong (RNA) (38%), including eight canonical splice-site variants, one missense variant and one stop-gain variant; two received PVS1_Moderate (RNA) and 14 received BP7_Strong (RNA). Integration of minigene RNA data changed ACMG scores by a mean of 2.7 points and led to reclassification of 13 variants (50%), including 12 downgrades from VUS to likely benign and one downgrade from likely pathogenic to VUS. These findings demonstrate that targeted sequencing of minigene-derived transcripts provides a scalable approach to evaluate splice-associated SDHB variants and improve variant classification.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.